About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

NOTCH1 mutations, found in 20% of CLL cases, are associated with poor outcomes in chemotherapy but not yet in treatment guidelines. A retrospective analysis showed improved PFS for NOTCH1-mutated CLL ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia. The post Women’s Health ...